Business Context and Reporting Period
This Form 8-K Current Report was filed by Alector, Inc. on March 29, 2022. The filing discloses the appointment of a new executive officer, specifically the Chief Medical Officer, effective May 23, 2022.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
- Base Salary: $475,000 annually.
- Performance Bonus: Eligible for up to 40% of base salary (prorated for the first year).
- Stock Option Grant: Fair value of approximately $3,900,000, vesting over four years.
- Restricted Stock Units (RSU): Fair value of approximately $975,000, vesting over three years.
Material Changes
The primary material change is the appointment of Gary Romano, Ph.D., M.D., as Chief Medical Officer. Dr. Romano brings over 25 years of experience in neurodegenerative diseases, having previously served as Chief Medical Officer at Passage Bio and in leadership roles at Janssen Pharmaceutical Companies of Johnson & Johnson and Merck.
Outlook, Risks, and Unusual Items
The filing outlines standard compensatory arrangements and severance terms (Tier 2 level) for the new appointee. There are no unusual items, forward-looking guidance, or specific risk factors disclosed in this document beyond the standard vesting conditions tied to continued service.
Investor Verification Checklist
- Verify the effective start date of Dr. Romano's employment (May 23, 2022).
- Review the full Offer Letter (Exhibit 10.1) for specific vesting schedules and performance metrics.
- Confirm the total equity grant value ($4,875,000 combined fair value) relative to the company's current stock price and dilution impact.
- Check for any subsequent filings regarding the integration of Dr. Romano into the executive team.